To the full analysis
Buyback calculator for CSPC Pharmaceutical Group
CSPC Pharmaceutical Group stock: key metrics
1093.HKCSPC Pharmaceutical Group had an operating margin of 15.3% and a return on invested capital (ROIC) of 11.8% in fiscal 2025.
Margins show how much of revenue is left over, returns on capital how hard the invested money works.
Daily figure as of 13 Nov 2026
Margins
- Gross margin
- Operating margin
- Net margin
Figures as a table
| Year | Gross margin | Operating margin | Net margin |
|---|---|---|---|
| 2006 | 17.3% | 1.7% | 0.4% |
| 2007 | 30.8% | 12.3% | 9.6% |
| 2008 | 33.4% | 17.2% | 15.1% |
| 2009 | 32.2% | 15.9% | 13.8% |
| 2010 | 29.2% | 13.1% | 9.7% |
| 2011 | 43.1% | 17.2% | 14.8% |
| 2012 | 43.5% | 17.5% | 52.1% |
| 2013 | 39.5% | 12.4% | 12.3% |
| 2014 | 38.2% | 14.1% | 11.6% |
| 2015 | 45.8% | 18.4% | 14.6% |
| 2016 | 51.0% | 20.7% | 17.0% |
| 2017 | 60.4% | 22.7% | 17.9% |
| 2018 | 66.4% | 20.1% | 17.4% |
| 2019 | 72.0% | 20.1% | 16.8% |
| 2020 | 74.9% | 21.8% | 20.7% |
| 2021 | 75.8% | 22.4% | 20.1% |
| 2022 | 71.9% | 21.9% | 19.7% |
| 2023 | 70.5% | 22.3% | 18.7% |
| 2024 | 70.0% | 18.5% | 14.9% |
| 2025 | 65.6% | 15.3% | 14.9% |
Returns on capital
- ROE
- ROIC
- ROA
Figures as a table
| Year | ROE | ROIC | ROA |
|---|---|---|---|
| 2006 | 0.6% | 1.6% | 0.3% |
| 2007 | 31.2% | 19.8% | 21.7% |
| 2008 | 20.9% | 32.2% | 11.9% |
| 2009 | 16.6% | 17.7% | 10.8% |
| 2010 | 11.1% | 21.6% | 42.9% |
| 2011 | 37.8% | 33.1% | 12.1% |
| 2012 | 200.0% | 16.2% | 16.0% |
| 2013 | 14.1% | 10.9% | 8.0% |
| 2014 | 12.4% | 11.7% | 8.0% |
| 2015 | 15.9% | 17.2% | 10.3% |
| 2016 | 18.6% | 22.9% | 12.7% |
| 2017 | 15.3% | 25.3% | 13.0% |
| 2018 | 18.7% | 26.6% | 12.1% |
| 2019 | 18.0% | 25.0% | 12.6% |
| 2020 | 21.9% | 29.9% | 16.3% |
| 2021 | 21.3% | 33.1% | 15.9% |
| 2022 | 20.9% | 33.2% | 15.1% |
| 2023 | 17.7% | 28.2% | 12.7% |
| 2024 | 13.7% | 17.2% | 9.9% |
| 2025 | 11.4% | 11.8% | 8.1% |
Data status and sources
- Score
- Daily value of 13 Nov 2026, recalculated nightly
- Price
- Closing price of 12 Nov 2026
- Latest annual report
- Fiscal year 2025, period end 31 Dec 2025
- Currency
- Amounts in US dollars, converted at the ECB reference rate of 12 Nov 2026 ($1 = HK$7.8782, $1 = CN¥6.6683)
- Source
- Financial statements, ratios and prices from Financial Modeling Prep (FMP), based on the company's reports. MEQIRI calculates the score and fair value from them.
Mandatory disclosures for this rating
- ; time horizon around 12 months
- Rated Strong, published since 7 Nov 2026 (in the score history since 2 Oct 2026)
- Valuation signal Fairly valued since 8 Nov 2026, previously Undervalued
- End-of-day prices, metrics cached for up to 24 hours
- Score and fair value are estimates from a disclosed model. They are not facts and not a price target.
- Produced by SSM Ventures UG (haftungsbeschränkt), responsible person Sven Brostmeyer, Managing Director, automatically according to the disclosed model.
- Not investment advice. Losses up to and including a total loss are possible. Personal circumstances are not considered.